GlobalData on MSN9d
FDA grants orphan drug status to Arbor Biotechnologies’ PH1The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) and rare paediatric disease designation ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received an average recommendation of “Moderate Buy” from ...
SG Americas Securities LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 50.8% ...
Since then, Alnylam has claimed approval for two more RNAis, Givlaari (givosiran) for acute hepatic porphyria (AHP) and Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1). RNAi uses small ...
Arbor Biotechnologies Inc.’s ABO-101 has been awarded orphan drug and rare pediatric disease designations by the FDA for the treatment of primary hyperoxaluria type 1 (PH1).
The FDA has granted a pair of designations, both orphan drug and rare pediatric disease, to ABO-101 (Arbor Biotechnologies) for the treatment of primary hyperoxaluria type 1 (PH1), according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results